TIRZ GLP-1 / GIP

Research Overview

TIRZ is a synthetic peptide investigated in metabolic research as a dual receptor agonist. It is supplied as a lyophilized powder in independently sealed sterile vials, allowing investigators to reconstitute material at the point of use according to specific experimental requirements.

This compound is studied across metabolic research models for activity on glucose response, energy regulation, and adipose tissue research. TIRZ represents the second generation of investigational metabolic peptides, dual-receptor compounds engaging both incretin pathways. SEMA acts at GLP-1 alone. TIRZ adds GIP for dual incretin engagement. RETA extends further to include glucagon receptor activity. TIRZ sits at the methodological middle of the family, with broader receptor coverage than first-generation single agonists but a more constrained signaling space than the third-generation triple agonist.

The dual-agonist mechanism makes TIRZ methodologically distinct in research design. Studies that examine receptor crosstalk between GLP-1 and GIP signaling pathways require a defined dual-receptor compound rather than a multi-receptor compound where additional receptor activity confounds interpretation. TIRZ fills this role in published research as the most pharmacologically characterized dual incretin agonist available for laboratory work.

For mechanism research, integrated pharmacology, and the published findings on dual incretin receptor research, see Tirzepatide Research. For comparative research between TIRZ and the single-agonist SEMA, see Semaglutide vs Tirzepatide. For comparative research between TIRZ and the triple-agonist RETA, see Tirzepatide vs Retatrutide Comparison.

Mechanism

TIRZ is engineered to engage two distinct receptor pathways simultaneously: GLP-1 and GIP. This dual-agonist mechanism distinguishes it from single-receptor (SEMA) and triple-receptor (RETA) compounds in the same investigational family.

The compound has been studied in peer-reviewed research for its effects on glucose homeostasis, lipid metabolism, and energy regulation in preclinical contexts. Investigators studying incretin receptor pharmacology design experiments around the hypothesis that simultaneous engagement of GLP-1 and GIP receptors produces effects that single-receptor compounds cannot reproduce, particularly in the integrated metabolic pharmacology and biased signaling pathways at the GLP-1 receptor that distinguish dual-agonist research from earlier-generation work.

Product Specifications

• Class: Dual agonist research peptide (GLP-1 / GIP)
• Purity: ≥99% (HPLC verified)
• Testing: HPLC + Mass Spectrometry
• Form: Lyophilized powder
• Container: Sterile vial
• Available Vial Sizes: 10mg, 30mg
• Storage: Refrigerated (2 to 8 degrees Celsius)
• Documentation: Batch-specific COA available

Reconstitution and Storage

TIRZ is supplied as lyophilized powder in independently sealed sterile vials. Reconstitution is performed by adding bacteriostatic or sterile water to the vial according to the volume protocol used in the specific research application. Reconstitution volume varies by intended working concentration; investigators selecting reconstitution methodology should reference established protocols for their experimental model.

Storage of lyophilized vials at minus 20 degrees Celsius preserves primary structural integrity and biological activity for two to three years for most well-prepared research peptides. Refrigerated storage at 2 to 8 degrees Celsius is acceptable for active inventory expected to be used within months. Once reconstituted, peptides return to aqueous-phase stability constraints and should be used within the documented stability window for the specific compound rather than relying on a generic timeline.

For a detailed treatment of the freeze-drying process, storage temperatures, shelf life expectations, and quality indicators researchers use to assess lyophilized material before reconstitution, see Lyophilized Peptides: Methodology and Stability.

Quality and Verification

Every Genevium batch is independently tested by third-party laboratories. Reverse-phase HPLC confirms purity. Mass spectrometry confirms identity. Nothing ships until the compound clears a 99%+ purity threshold.

A batch-specific Certificate of Analysis is published for every order and is retrievable by batch number on the COA Lookup page. The COA documents purity by HPLC, identity by mass spectrometry, and the analytical conditions under which both were measured.

Research Applications

TIRZ is studied in research contexts where investigators require a defined dual-receptor incretin agonist for in vitro receptor activity assays, ex vivo tissue model systems, or pre-clinical animal model research on glucose homeostasis, lipid metabolism, and energy regulation. The dual-agonist mechanism allows investigators to study GLP-1 and GIP receptor crosstalk in ways that single-receptor compounds cannot support, while keeping the receptor space defined enough to isolate dual incretin pharmacology from the additional glucagon receptor activity present in triple-agonist research.

Frequently Asked Questions

How does TIRZ differ from SEMA and RETA?

TIRZ engages two receptor pathways: GLP-1 and GIP. SEMA engages one: GLP-1 alone. RETA engages three: GLP-1, GIP, and glucagon. The three compounds therefore represent successive generations of metabolic peptide research. TIRZ sits at the methodological middle, with broader receptor coverage than first-generation single agonists and tighter receptor focus than third-generation triple agonists. For the full comparative research overviews, see Semaglutide vs Tirzepatide and Tirzepatide vs Retatrutide Comparison.

How is TIRZ reconstituted for research use?

Bacteriostatic or sterile water is added to the lyophilized vial according to the volume protocol used in the specific research application. Reconstitution volume varies by intended working concentration. Investigators should reference established protocols for their experimental model rather than rely on a generic dilution.

What vial sizes are available?

TIRZ is offered in three vial sizes for research applications: 10mg, 20mg, and 30mg. Each vial is supplied as lyophilized powder in an independently sealed sterile container, with batch-specific Certificate of Analysis documenting purity and identity for the lot.

How is TIRZ quality verified?

Each batch is tested independently by third-party laboratories using reverse-phase HPLC for purity quantification and mass spectrometry for identity confirmation. The Certificate of Analysis is retrievable by batch number from the COA Lookup page. Genevium ships nothing below 99% HPLC purity.

For laboratory solution preparation, the reconstitution calculator determines the bacteriostatic water volume required to achieve a target concentration for a given quantity of lyophilized peptide.